Argenx, a global biotech company, has consistently presented a robust performance in recent times. Its 2025 half-year financial results and Q2 business updates demonstrate a satisfying growth trajectory. The company's earnings per share and revenue have beat the estimates, and its Vyvgart sales have almost doubled, reaching $949 million. In addition, there seems to be substantial progress with its macrocyclic peptides project in collaboration with Unnatural Products. The company has recently inked a deal worth $1.5 billion. Argenx's innovations have resulted in a strong buy rating from several analysts, including those from Deutsche Bank and BofA Securities, marking them as an exciting long-term investment opportunity in bio-tech. Its stock has been upgraded to Buy from Hold and also achieved an all-time high at 689.13 USD. Despite a 54.3% drop in its trading volume, Argenx managed to gain 0.52% recently. However, while it is soaring in the market, the FDA is considering taking regulatory action on Argenx's Vyvgart Hytrulo amid reports of severe worsening of the disease. Nonetheless, ARGENX's overall market position and financial performance remain strong.
argenx News Analytics from Wed, 19 Feb 2025 08:00:00 GMT to Sat, 02 Aug 2025 20:36:45 GMT -
Rating 7
- Innovation 7
- Information 9
- Rumor 3
